Literature DB >> 20527604

Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers.

Asim Qureshi1, Shahid Pervez.   

Abstract

OBJECTIVE: To determine the scoring of Estrogen Receptor (ER) status in carcinoma breast by Allred method that is essentially bimodal and to compare the results with a conventional scoring system.
MATERIALS AND METHODS: A retrospective, comparative study carried out at Aga Khan University Hospital Section of Histopathology over a period of 18 months, i.e., Jan 2005 to June 2006. Anti ER antibody (clone D07) was used for all IHC stains using envision detection system. ER stains of 860 consecutive breast cancer cases were reviewed and rescored by both conventional and Allred method of ER scoring.
RESULTS: Comparison of results showed that there was a substantial decrease in weak positive cases from 18% to 5% by rescoring using Allred scoring system compared to conventional scoring. The data was analyzed using chi square test.
CONCLUSION: The sensitivity and specificity of Allred method were calculated; Sensitivity of Allred method was 99.4% & Specificity of Allred method was 99.5% whereas sensitivity and specificity of conventional method was 88.0% and 84% respectively

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20527604

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  22 in total

1.  High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma.

Authors:  T Akaike; J Qazi; A Anderson; F S Behnia; M M Shinohara; G Akaike; D S Hippe; H Thomas; S R Takagishi; K Lachance; S Y Park; E S Tarabadkar; J G Iyer; A Blom; U Parvathaneni; H Vesselle; P Nghiem; S Bhatia
Journal:  Br J Dermatol       Date:  2020-06-16       Impact factor: 9.302

2.  Heterogeneous Associations Between Obesity and Reproductive-Related Factors and Specific Breast Cancer Subtypes Among Hong Kong Chinese Women.

Authors:  Priscilla Ming Yi Lee; Chi Hei Kwok; Wing Cheong Chan; Cherry Wu; Koon-Ho Tsang; Sze-Hong Law; Yiu-Cheong Yeung; Feng Wang; Xiaohong R Yang; Lap Ah Tse
Journal:  Horm Cancer       Date:  2020-06-03       Impact factor: 3.869

3.  Expression of Kallikrein-Related Peptidase 6 in Primary Mucosal Malignant Melanoma of the Head and Neck.

Authors:  Julia Thierauf; Johannes A Veit; Jochen K Lennerz; Stephanie E Weissinger; Annette Affolter; Johannes Döscher; Christoph Bergmann; Andreas Knopf; Jennifer Grünow; Lisa Grünmüller; Cornelia Mauch; Peter K Plinkert; Thomas K Hoffmann; Jochen Hess
Journal:  Head Neck Pathol       Date:  2016-11-14

4.  Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma.

Authors:  Yaqing Li; Ruixia Huang; Xiaoli Li; Xiaoran Li; Dandan Yu; Mingzhi Zhang; Jianguo Wen; Mariusz Adam Goscinski; Claes G Trope; Jahn M Nesland; Zhenhe Suo
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

5.  Female sex hormone receptors in gallbladder cancer.

Authors:  Ramanathan Saranga Bharathi; Rajinder Singh; Rajesh Gupta; Ganga Ram Verma; Naveen Kalra; K Kiran; Kusum Joshi
Journal:  J Gastrointest Cancer       Date:  2015-06

6.  Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients.

Authors:  Nasr M A Allahloubi; Abdel-Rahman N Zekri; Mohamed Ragab; Marwa Mohanad; Ola S Ahmed; Salem Eid; Mohamed Ghareeb; Iman Gouda; Abeer A Bahnassy
Journal:  Biochem Genet       Date:  2022-02-19       Impact factor: 1.890

7.  Study of angiogenesis in invasive breast carcinoma by morphometry and immunohistochemistry.

Authors:  J K Bhatia; Tripta Chaudhary; Dibyajyoti Boruah; Reena Bharadwaj
Journal:  Med J Armed Forces India       Date:  2021-12-16

8.  Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma.

Authors:  Qiong Gan; Suzanne Crumley; Russell R Broaddus
Journal:  Int J Gynecol Pathol       Date:  2019-01       Impact factor: 2.762

9.  Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.

Authors:  Tanya D Russell; Sonali Jindal; Samiat Agunbiade; Dexiang Gao; Megan Troxell; Virginia F Borges; Pepper Schedin
Journal:  Am J Pathol       Date:  2015-09-04       Impact factor: 4.307

10.  A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Authors:  Cynthia X Ma; Vera Suman; Matthew P Goetz; Donald Northfelt; Mark E Burkard; Foluso Ademuyiwa; Michael Naughton; Julie Margenthaler; Rebecca Aft; Richard Gray; Amye Tevaarwerk; Lee Wilke; Tufia Haddad; Timothy Moynihan; Charles Loprinzi; Tina Hieken; Erica K Barnell; Zachary L Skidmore; Yan-Yang Feng; Kilannin Krysiak; Jeremy Hoog; Zhanfang Guo; Leslie Nehring; Kari B Wisinski; Elaine Mardis; Ian S Hagemann; Kiran Vij; Souzan Sanati; Hussam Al-Kateb; Obi L Griffith; Malachi Griffith; Laurence Doyle; Charles Erlichman; Matthew J Ellis
Journal:  Clin Cancer Res       Date:  2017-09-05       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.